Core Viewpoint - The innovative pharmaceutical stocks have shown significant gains, driven by the upcoming 44th JPMorgan Healthcare Conference, where multiple Chinese innovative drug companies are set to participate [1] Group 1: Stock Performance - Innovent Biologics (01530) increased by 6.35%, trading at HKD 28.82 [1] - WuXi AppTec (02359) rose by 7.22%, trading at HKD 118.8 [1] - Lepu Biopharma-B (02157) saw a rise of 6.64%, trading at HKD 28.9 [1] - Galenica-B (01672) increased by 4.09%, trading at HKD 12.97 [1] - Genscript Biotech (01952) rose by 3.97%, trading at HKD 40.84 [1] Group 2: Conference Participation - The 44th JPMorgan Healthcare Conference is set to begin on January 12, 2026, in San Francisco, with several Chinese innovative drug companies confirming their attendance [1] - Key speakers include WuXi AppTec, WuXi Biologics, and WuXi AppTec's subsidiary, along with innovative drug companies such as BeiGene, Zai Lab, Ascentage Pharma, and Legend Biotech [1] - A total of 17 companies, including Hengrui Medicine, Baillie Gifford, Innovent Biologics, and Rongchang Biologics, will participate in the Asia-Pacific session [1] Group 3: Industry Insights - According to Guojin Securities, the conference serves as a critical platform for domestic pharmaceutical companies to showcase their core molecular product capabilities and advance overseas business development collaborations [1] - The industry is transitioning back to a phase of global value verification for products, with ongoing clinical advancements, significant data releases, and improved competitive dynamics driving multiple rounds of revaluation for product global value and corporate valuations [1] - Huayuan Securities indicates that the Chinese pharmaceutical industry has largely completed the transition from old to new growth drivers, with innovative drugs significantly opening new growth trajectories for companies [1]